Health Eli Lilly’s Combination Obesity Drug Achieves 23% Weight Loss in Diabetic Patients, Surpassing Zepbound October 1, 2026 Eli Lilly has announced groundbreaking results for its experimental combination obesity treatment, reporting that eloraTZP achieved 23.3% average weight loss in patients battling both obesity or overweight and type 2…